Taltz (ixekizumab) / Eli Lilly - LARVOL DELTA

A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy (clinicaltrials.gov) - P3 | N=308 | Active, not recruiting | Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Recruiting ➔ Active, not recruiting

Enrollment closed • Dermatology • Immunology • Psoriasis • Psoriatic Arthritis • IL17A

IGA NEPHROPATHY FOLLOWING RISANKIZUMAB THERAPY FOR PSORIATIC ARTHRITIS: A CASE REPORT (ISN-WCN 2026) - "He was diagnosed with psoriatic arthritis in 2018 and treated sequentially with brodalumab, adalimumab, and ixekizumab, but these agents failed to adequately control his symptoms. While IgAN has been reported in association with the IL-12/23p40 inhibitor ustekinumab, no previous case of risankizumab-associated IgAN has been described. Further accumulation of biologic-associated IgAN cases, including those involving IL-23p19 inhibition, may help elucidate the underlying disease mechanisms."

Case report • Clinical • Crohn's disease • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Glomerulonephritis • IgA Nephropathy • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Psoriasis • Psoriatic Arthritis • Renal Disease • Rheumatology • Seronegative Spondyloarthropathies • Ulcerative Colitis • IL12A • IL23A • IL4

Comparative effectiveness and predictors of remission between adalimumab and ixekizumab in patients with psoriatic arthritis: findings from the 'AIRE' multicentre study. (PubMed, RMD Open) - "This RWE study showed that ADA and IXE provide similar 12-month joint outcomes, while IXE showed a faster skin response. Baseline demographic and clinical features affect the chance of remission, highlighting the importance of personalised treat-to-target approaches in PsA."

Clinical • HEOR • Journal • Dermatology • Immunology • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A

Comparison of the Effects and Safety of Planned Limited-Time Withdrawal Versus Continuous Maintenance of Interleukin Inhibitors in Patients with Psoriasis: A Systematic Review and Network Meta-Analysis. (PubMed, Dermatol Ther (Heidelb)) - "Compared with continued treatment, planned withdrawal of anti-IL therapy is associated with a largely superior risk of relapse, without any reduction in the incidence of adverse events. Moreover, bimekizumab withdrawal demonstrated better outcomes than ixekizumab withdrawal did according to the PASI90 outcome."

Journal • Retrospective data • Review • Dermatology • Immunology • Psoriasis

Development of Celiac Disease After Immunotherapy: A Case Series. (PubMed, Gastro Hep Adv) - "Celiac disease developed in 3 patients after initiating biologic therapy: a 21-year-old female with psoriasis receiving ixekizumab (interleukin-17 antagonist) and risankizumab (interleukin-23 antagonist); a 49-year-old female with invasive ductal carcinoma of the breast after pertuzumab (human epidermal growth factor receptor 2 antagonist); and an 82-year-old male taking cabozantinib (multityrosine kinase inhibitor) for renal cell carcinoma. We have identified 3 cases of celiac disease that presented after initiating new immune-modulating medications. It is important to consider celiac disease and nonceliac villous atrophy in the differential for diarrhea developing during or after a new therapy as it heavily impacts management and may eliminate the need for alternate therapies that include steroid courses, cessation of therapy, or even gluten-free diet."

Journal • Breast Cancer • Celiac Disease • Dermatology • Genito-urinary Cancer • Immunology • Oncology • Psoriasis • Renal Cell Carcinoma • Solid Tumor • HER-2

Real-World Comparative Risk of Infections with Biologic Therapy in Pediatric Psoriasis: A Nationwide Cohort Study (AAD 2026) - "Methods This new-user cohort study used US claims data (December 2016-June 2023) to identify children aged 6 to 17 years with psoriasis and compared the risk of inpatient infections and outpatient infections requiring antimicrobial treatment in those initiating etanercept, ustekinumab, and interleukin -17 inhibitors (IL-17i: secukinumab or ixekizumab). Conclusions In this real-world cohort study among children with psoriasis treated with biologics, the risk of outpatient infections requiring treatment was similar between initiators of IL-17i, etanercept and ustekinumab. No serious inpatient infections were observed."

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Infectious Disease • Pediatrics • Psoriasis

Efficacy of Biologics and Small Molecules for Pediatric Plaque Psoriasis: A Systematic Review of Randomized Control Trials (AAD 2026) - "Systemic therapies evaluated were apremilast (22.1%, 163/738), etanercept (19.9%, 147/738), secukinumab (16.5%, 122/738), ixekizumab (15.6%, 115/738), adalimumab (10.4%, 77/738), ustekinumab (9.9%, 73/738), and guselkumab (5.6%, 41/738). No treatment-related deaths were reported. Our results indicate that interleukin-17 inhibitors, particularly secukinumab and ixekizumab, achieve the highest efficacy in pediatric plaque psoriasis with favorable short-term safety profiles."

Clinical • Review • Dermatology • Immunology • Infectious Disease • Inflammation • Pediatrics • Psoriasis • IL17A

Ixekizumab Demonstrates Effectiveness in Reducing the Severity of Musculoskeletal Symptoms in Patients with Psoriasis, Without Reported Psoriatic Arthritis: Results from the Psoriasis in Special Areas (PSoSA) Study (AAD 2026) - "Ixekizumab demonstrates marked effectiveness in reducing the severity of musculoskeletal symptoms in patients with PsO, without reported PsA. These findings underscore the importance of effective and early treatment of musculoskeletal symptoms, as they may be indicative of future PsA development, particularly in patients considered at higher risk for progression to PsA, such as those with PsO and nail involvement."

Clinical • Dermatology • Immunology • Inflammatory Arthritis • Musculoskeletal Diseases • Musculoskeletal Pain • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Specialty Pharmacy Interventions in Plaque Psoriasis and Psoriatic Arthritis: A 4-Year Institutional Review (AAD 2026) - "We identified n=911 with plaque psoriasis and/or psoriatic arthritis, with the five most prescribed systemics being: risankizumab-rzaa(RIS)=28.2%, apremilast(APR)=22.7%, secukinumab(SEC)=13.1%, ustekinumab(UST)=11.6%, ixekizumab(IXE)=11.3%. While RIS was the most prescribed medication, APR had the most interventions in each category, most notably interventions related to side-effects, drug-drug interactions, medication discontinuation, or adjunctive medications or healthcare visits required to address an issue. This study also highlights the benefits of an academic SP to improve patient care and medication management."

Clinical • Review • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Ixekizumab Demonstrates Continued Improvements in Nail and Scalp Psoriasis through 52 Weeks: Final Results from the Psoriasis in Special Areas (PSoSA) Study (AAD 2026) - "In the PSoSA study, IXE demonstrated continued improvements in nail and scalp psoriasis over 52 weeks. These findings reinforce IXE’s role in managing psoriasis manifestations in high-impact areas in a real-world setting."

Clinical • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Seronegative Spondyloarthropathies

Cost Effectiveness Analysis of Biological Drugs Targeting IL-17 Pathway in Plaque Psoriasis From the Perspective of the Brazilian Private Healthcare System (AAD 2026) - "For PASI 100, the estimated costs were R$160,528 for brodalumab, R$187,807 for bimekizumab, R$252,538 for ixekizumab, and R$335,867 for secukinumab. Immunobiologic therapies are effective and safe for the management of moderate-to-severe psoriasis, with IL-17 inhibitors representing an important treatment class. In this analysis, brodalumab was associated with the most favorable cost-effectiveness profile among IL-17 inhibitors. These findings suggest potential implications for optimizing clinical outcomes and healthcare resource allocation within the Brazilian Supplemental Health System."

Cost effectiveness • HEOR • Dermatology • Immunology • Psoriasis • IL17A

Early skin improvement, rather than treatment assignment, is associated with early nail improvement in moderate-severe nail psoriasis (AAD 2026) - "Ixekizumab 80 mg q2weeks is significantly superior to etanercept and placebo in causing skin and nail improvement in moderate-severe psoriasis patients. Skin improvement, not treatment assignment, is associated with nail improvement. Concomitant tobacco use impairs nail psoriasis improvement regardless of treatment."

Dermatology • Immunology • Psoriasis

Concomitant therapy with ixekizumab plus tirzepatide in adults with psoriatic arthritis and overweight or obesity demonstrated superior disease control compared to ixekizumab alone: results from the Ph3b TOGETHER-PsA trial (AAD 2026) - No abstract available

Clinical • Late-breaking abstract • Genetic Disorders • Immunology • Inflammatory Arthritis • Obesity • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Comparative Outcomes of Immunomodulatory Versus Conventional Therapies in Congenital Ichthyosis: A TriNetX Cohort Study (AAD 2026) - "Patients were divided into two cohorts: an immunomodulatory group (n=1,364) including dupilumab, azathioprine, ustekinumab, ixekizumab, infliximab, adalimumab, secukinumab, cyclosporine, and JAK inhibitors and a conventional therapy group (n=1,364) including keratolytics, isotretinoin, acretin, adapalene, etretinate, adapalene, and tretinoin. Immunomodulatory therapies, particularly biologics, were associated with a reduced burden of inflammatory comorbidities, suggesting potential improvements in disease control and quality of life. Larger studies are warranted to delineate the long-term effectiveness of specific biologics in this population."

Immunomodulating • Acne Vulgaris • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Vitiligo

Risk of infections in patients with psoriasis treated with biologic agents and new oral small molecules. BIOBADADERM Registry. (AAD 2026) - " We analyzed crude incidence rates of overall, serious, recurrent, and infections of special interest in patients treated with etanercept, infliximab, certolizumab, adalimumab, ustekinumab, secukinumab, ixekizumab, brodalumab, bimekizumab, guselkumab, risankizumab, tildrakizumab, apremilast, and dimethyl fumarate. Modern systemic therapies for psoriasis show a favorable infection safety profile in real-world settings. IL-17 inhibitors appear to increase the risk of Candida infections, while some biologics may reduce the incidence of respiratory and viral infections."

Clinical • Candidiasis • Dermatology • Human Papillomavirus Infection • Immunology • Infectious Disease • Nephrology • Novel Coronavirus Disease • Psoriasis • Respiratory Diseases • IL17A

Beyond Trial-and-Error: Mechanism-Guided Use of Biologics in Scalp Psoriasis (AAD 2026) - "Ustekinumab offered modest scalp improvement but lacked dedicated trials. IL-17 inhibitors (secukinumab, ixekizumab, brodalumab, bimekizumab) consistently produced the most rapid clearance, with several maintaining high rates of complete response in long-term follow-up. IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab) provided excellent durability, with real-world evidence confirming sustained clearance. No scalp-specific outcomes were reported for certolizumab... Biologic selection in scalp psoriasis can move beyond trial-and-error toward mechanism-guided therapy. IL-17 inhibitors are best suited for rapid scalp clearance, while IL-23 inhibitors may optimize long-term durability. These findings support the development of a practical, scalp-specific treatment algorithm to address one of the most visible and burdensome manifestations of psoriasis."

Dermatology • Immunology • Psoriasis • CD8 • IL22 • IL23A

Risk of superficial fungal infection in patients with psoriasis receiving Interleukin-17 inhibitors – A Propensity score-matched retrospective cohort study (AAD 2026) - "Background: IL-17 inhibitors (IL-17i), including secukinumab and ixekizumab, are effective in managing moderate-to-severe psoriasis (PsO) but may impair mucocutaneous immunity and increase the risk of superficial fungal infections (SFI). Among the 1283 IL-17i–treated patients and 3849 matched cohort, iL-17i treatment had significantly higher odds of developing SFI than non-il17i-treatment (OR 1.94; 95% CI 1.56 –2.40; P < 0.001). Diabetes is an independent risk factor of SFI (OR 2.39; 95% CI 1.79–3.19). The elevated risk was more prominent among females (OR 2.24; 95% CI 1.73–2.90) and patients aged <60 years (OR 2.09; 95% CI 1.64–2.67)."

Retrospective data • Candidiasis • Dermatology • Diabetes • Immunology • Infectious Disease • Metabolic Disorders • Psoriasis • IL17A

Early and Maintained Treat-to-Target Response with Ixekizumab up to 5 Years in Moderate-to-Severe Psoriasis: A Post-Hoc Analysis of UNCOVER-3 (AAD 2026) - P3 | "Additionally, BSA<3% and BSA<1% response rates were achieved by 62.1% (n=239/385) and 50.9% (n=196/385) of patients at Week12; among these responders, 97.7% (n=128/131) and 88.7% (n=102/115) maintained these targets at Week264, respectively. These findings demonstrate that early and continuous treatment with ixekizumab results in long-term improvements in skin clearance to 5 years across clinically important T2T outcomes consistent with guidelines recommendations."

Retrospective data • Dermatology • Immunology • Psoriasis

Comparative risk of psoriatic arthritis in psoriasis patients on immunomodulators (AAD 2026) - "The immunomodulatory agents assessed included Adalimumab, Infliximab, Ixekizumab, Secukinumab, Tildrakizumab, Certolizumab pegol, Risankizumab, Etanercept, Guselkumab, and Ustekinumab. Inhibition of this inflammation by immunomodulators could impede PsA progression. Physicians can consider Risankizumab, Guselkumab, and Ustekinumab as treatment options for PsO patients with PsA risk factors to mitigate disease progression and improve patients’ quality of life."

Clinical • Immunomodulating • Cardiovascular • Dermatology • Diabetes • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Gout • Hypertension • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Metabolic Disorders • Obesity • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL23A • JAK1 • JAK3 • TNFA

Beyond Monotherapy: Synergistic TYK2 and IL-23 Inhibition for the Effective Management of Treatment-Resistant Psoriasis (AAD 2026) - "Over several years, he failed multiple therapies including topical corticosteroids, oral prednisone, and systemic immunosuppressants (methotrexate, cyclosporine, mycophenolate). Biologic agents such as dupilumab, ixekizumab, and apremilast were also ineffective...Initial risankizumab monotherapy (IL-23 inhibitor) reduced BSA from 65% to 20%. Due to incomplete clearance, deucravacitinib (TYK2 inhibitor) was added, resulting in further improvement to 4% BSA over 16 months. The combination was well tolerated with no adverse effects. This case highlights the potential efficacy of dual IL-23 and TYK2 inhibition and supports individualized, flexible treatment strategies for refractory psoriasis."

Monotherapy • Atopic Dermatitis • Dermatology • Immunology • Pruritus • Psoriasis • IL17A • IL23A • IL4 • TYK2

PRT19 A Product Theater for Taltz® (ixekizumab) and Zepbound® (tirzepatide) Injection including an Affordability Program for Eligible Taltz Patients Prescribed Zepbound (AAD 2026) - "Sponsored by: Lilly USA, LLC DESCRIPTION Join us for this Lilly event! Please see Full Prescribing Information for Zepbound including Boxed Warning and Medication Guide at the product theater or on www.zepbound.lilly.com"

Clinical

Safety Outcomes of IL-23 Versus IL-17 Inhibitors in Psoriasis: A Multicenter Real-World Study (AAD 2026) - "Adults (≥18 years) with psoriasis initiating an IL-23 inhibitor (guselkumab, risankizumab, tildrakizumab) were compared to those commencing an IL-17 inhibitor (secukinumab, ixekizumab, brodalumab). This first multicenter, real-world head-to-head comparison of IL-23 and IL-17 inhibitors in psoriasis demonstrates a therapeutic trade-off: IL-23 agents reduce infection and mortality risks but increase malignancy and NMSC risks relative to IL-17 inhibitors. These findings offer pivotal evidence to inform individualized, long-term biologic selection in psoriasis, addressing a major gap in dermatologic care."

Clinical • Real-world • Real-world evidence • Dermatology • Genetic Disorders • Herpes Zoster • Immunology • Infectious Disease • Non-melanoma Skin Cancer • Pneumonia • Psoriasis • Respiratory Diseases • Septic Shock • Skin Cancer • Solid Tumor • Varicella Zoster • IL17A • IL23A

BeNeBio: Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (clinicaltrials.gov) - P4 | N=244 | Completed | Sponsor: Radboud University Medical Center | Active, not recruiting ➔ Completed

Head-to-Head • Trial completion • Dermatology • Immunology • Psoriasis • IL17A

Comparative Real-World Risk of Candidiasis in Ankylosing Spondylitis Treated with Secukinumab Versus Ixekizumab (EULAR 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Ankylosing Spondylitis • Candidiasis • Immunology • Inflammatory Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Ixekizumab and Concomitant Tirzepatide Achieved Early Disease Control in Adults with Psoriatic Arthritis and Obesity/Overweight: Phase 3b TOGETHER-PsA Trial (EULAR 2026) - No abstract available

Clinical • P3 data • Genetic Disorders • Immunology • Inflammatory Arthritis • Obesity • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies